Opportunity BasketPharmaCatalyst Intelligence Service
A boutique research service that employs pharmaceutical domain experts (former drug commercialization managers, hospital procurement analysts, pharmacy benefit managers) to manually track non-innovative drug portfolio expansions, manufacturing capacity increases, pricing power signals, and volume acceleration across Chinese pharmaceutical companies. Analysts produce weekly 'Dark Horse Alerts'—short reports identifying 3–5 stocks with imminent profit inflection points, backed by supply-chain evidence, procurement data, and regulatory filings that retail tools miss.
46 weeks • 70% confidence
Value Proposition
Beats financial screening tools because it uses human domain expertise to spot *why* a generic drug company's margins are about to explode (e.g., new manufacturing plant online, hospital formulary wins, price negotiation leverage post-volume milestone)—not just backward-looking metrics. Investors get 4–8 week lead time before the stock moves, vs. 2–3 weeks with public announcements.
Target Audience
Chinese retail investors with 500k–5M CNY portfolios seeking alpha; active traders and small investment clubs on platforms like Snowball, East Money, Tiger Broker
Key Features
- Weekly 'Dark Horse Alert' reports (3–5 stock picks with 6–12 month catalysts)
- Supply-chain verification: procurement announcements, manufacturing capacity filings, hospital tender wins
- Pricing power analysis: historical price increases, volume thresholds, negotiation cycles
- And more, with full implementation detail...
Tech Stack
Unlock the full solution
You're seeing a preview. Unlock the complete value proposition, every feature, the full tech stack, the monetization model, and the week-by-week build roadmap, plus a downloadable PDF.
Sign up free to continue3 free solution credits on signup
The build plan is behind the wall
Subscribers get the full monetization model, pricing strategy, and the complete week-by-week roadmap to build this.
Sign up freeOriginal Problem
Chinese retail investors struggle to identify undervalued pharmaceutical stocks with explosive growth potential before they surgeChinese stock market investors are desperately seeking ways to discover pharmaceutical companies with hidden growth catalysts (like non-innovative drugs with massive profit expansion) before these stocks become 10x winners. Current financial analysis tools and stock screening methods fail to surface these 'dark horse' opportunities early, causing investors to miss life-changing returns. The pain is acute because pharmaceutical stocks with 11x net profit growth are rare, and investors feel they're always entering too late.
Score: 46.9%